Impaired type I interferon signaling activity implicated in the peripheral blood transcriptome of preclinical Alzheimer's disease

Background Subjective or objective subtle cognitive decline (SCD) is considered the preclinical manifestation of Alzheimer's disease (AD), which is a potentially crucial window for preventing or delaying the progression of the disease. Methods To explore the potential mechanism of disease progression and identify relevant biomarkers, we compre-hensively assessed the peripheral blood transcriptomic alterations in SCD, covering lncRNA, mRNA, and miRNA. Findings Dysregulated protein-coding mRNA at both gene and isoform levels implicated impairment in the type I interferon signaling pathway in SCD. Specifically, this pathway was regulated by the transcription factor STAT1 and ncRNAs NRIR and has-miR-146a-5p. The miRNA-mRNA-lncRNA co-expression network revealed hub genes for the interferon module. Individuals with lower interferon signaling activity and lower expression of a hub gene STAT1 exhibited a higher conversion rate to mild cognitive impairment (MCI). Interpretation Our findings illustrated the down-regulation of interferon signaling activity would potentially increase the risk of disease progression and thus serve as a pre-disease biomarker.Copyright (c) 2022 The Authors. Published by Elsevier B.V.

Automated summary

This study comprehensively assessed the peripheral blood transcriptomic alterations in individuals with subtle cognitive decline (SCD) and found that impairment in the interferon signaling pathway may be related to the progression of Alzheimer's disease. The down-regulation of interferon signaling activity was found to increase the risk of disease progression and could serve as a pre-disease biomarker.